Stem cell drugs surprise researchers: Could lead to better drugs in the future

trader32176
Posts: 3265
Joined: Fri Jun 26, 2020 5:22 am

Stem cell drugs surprise researchers: Could lead to better drugs in the future

Post by trader32176 »

Stem cell drugs surprise researchers: Could lead to better drugs in the future

5/28/21


https://www.eurekalert.org/pub_releases ... 052821.php


Your immune system is always busy fighting incoming threats. It consists of a system of cells, and when there is a shortage of cells, it affects the performance of the immune system.

This is seen in e.g. cancer patients following chemotherapy. This is because chemotherapy targets all the cells in your body, including the stem cells in your bone marrow, which were meant to develop into new immune cells. This means that the immune system then lacks cells to fight new infections.

There are drugs that can harvest stem cells from the bone marrow, so that they can be returned to the patients after treatment. They then develop into new immune cells, enabling the body to once again fight incoming threats. But previously, we lacked detailed knowledge of how these drugs worked.

Now, a study conducted in mice by researchers at the University of Copenhagen demonstrates how the medicine works at the cell level - and, surprisingly, how one of the two applied and tested drugs is more effective than the other, despite the fact that the other drug, on paper, appears to be the most effective of the two. This discovery may not just help improve stem cell transplantation; it may also lead to improved drugs in the future.

"We have tested two drugs for stem cell transplantation which appear to have the same effect. What they do is block a receptor, causing the bone marrow to release stem cells into the blood. What the new study shows, though, is that they do not just block the receptor; one of the two drugs also affects other signalling pathways in the cell. And in short, that makes it more effective than the other of the two drugs," says PhD Student Astrid Sissel Jørgensen from the Department of Biomedical Sciences at the University of Copenhagen.

"We used to believe that all we had to do was block the receptor, and that the two drugs had the same effect. It now appears that there is more to it," she says.

The drugs tested by the researchers mobilize stem cells by acting as CXCR4 receptor antagonists. This means that they inhibit or reduce activity of the receptor. Several drugs target this receptor, including drugs inhibiting HIV replication.

"The drugs not only block the receptor's normal signalling. One of the two drugs we have tested also affect some of the other cell pathways and even make the receptor withdraw into the cell and disappear from the surface," explains Professor Mette Rosenkilde, who is the corresponding author of the study. The study results reveal that one of the two drugs makes the bone marrow release more stem cells into the blood.

This knowledge about how drugs affect cell pathways differently is also known as biased signalling. And it is things like these that make one of the drugs more effective in practice than on paper.

According to the researchers, the new knowledge on biased signalling challenges our current view of these drugs.

"The results of our study directly influence our view of drugs used for stem cell transplantation. In the long term, though, it may also affect our view of future drugs, and how new drugs should be designed to have the best possible effect, both in connection with stem cell mobilisation, but also for treating HIV infections, where this particular receptor also plays a main role," says Mette Rosenkilde.
curncman
Posts: 1077
Joined: Fri Jun 26, 2020 8:27 am

Re: Stem cell drugs surprise researchers: Could lead to better drugs in the future

Post by curncman »

Trader thanks for posting throwing light on the great development of stemcell therapies. TSOI is leader in the advance stem cell therapy in addressing cancers and SAR-CVO2/ARDS/MERS and I hope the BIG PHARMA partners with TSOI in immediate future to deliver NON-TOXIC drugs in the post pandemic era!

As you know TSOI has JADICELLS for repair of lung damage, JADICELLS for treatment of CTE, STEMVACS-V-ips-TEC for treatment of many cancers, Quadramune for keeping immune system intact against COVID-19, Neuroleukin for Mental Health, NanoStilbene for Cancer Immunaotherapy and most importantly JADICELLS may find use in treatment of OPIODS VAPING and list goes on!
trader32176
Posts: 3265
Joined: Fri Jun 26, 2020 5:22 am

Re: Stem cell drugs surprise researchers: Could lead to better drugs in the future

Post by trader32176 »

the science is always changing as we both know curncman .

some of these articles are a little behind you , so sometimes it takes a little bit of time for the published stuff to catch up .

8-)
curncman
Posts: 1077
Joined: Fri Jun 26, 2020 8:27 am

Stem Cell Treatment for Idiopathic pulmonary fibrosis (IPF)

Post by curncman »

Stem Cell Treatment for Idiopathic pulmonary fibrosis (IPF)

curncman
Posts: 1077
Joined: Fri Jun 26, 2020 8:27 am

Stem Cells and its therapeutic applications | Dr. G. Muthukumar

Post by curncman »

Stem Cells and its therapeutic applications | Dr. G. Muthukumar


curncman
Posts: 1077
Joined: Fri Jun 26, 2020 8:27 am

STEM CELL THERAPY: The Best Anti-Aging Therapy

Post by curncman »

STEM CELL THERAPY: The Best Anti-Aging Therapy

curncman
Posts: 1077
Joined: Fri Jun 26, 2020 8:27 am

BMT CTN 1302: maintenance ixazomib following alloHCT in patients with high-risk myeloma

Post by curncman »

BMT CTN 1302: maintenance ixazomib following alloHCT in patients with high-risk myeloma




Taiga Nishihori, MD, Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the results from the Phase II BMT CTN 1302 trial (NCT02440464) of maintenance ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Fludarabine, melphalan and bortezomib were administered as a conditioning treatment and 12 rounds of ixazomib or placebo maintenance were administered after transplant. Dr Nishihori reports no significant progression-free survival (PFS) or overall survival (OS) between the ixazomib and placebo groups. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
curncman
Posts: 1077
Joined: Fri Jun 26, 2020 8:27 am

Current and future state of T cell therapy manufacturing - Closing, automating and preparing

Post by curncman »

Current and future state of T cell therapy manufacturing - Closing, automating and preparing


curncman
Posts: 1077
Joined: Fri Jun 26, 2020 8:27 am

Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi

Post by curncman »

Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi

https://www.yahoo.com/finance/news/bris ... 04956.html

Bristol Myers Squibb BMY announced positive top-line results from the TRANSFORM study on Breyanzi (lisocabtagene maraleucel), a CD19-directed CAR T cell therapy.

Breyanzi is a CD19-directed genetically modified autologous T cell immunotherapy. It was approved in February 2021 for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

The TRANSFORM study has been designed to evaluate Breyanzi’s potential in the second-line setting for patients with relapsed or refractory large B-cell lymphoma against the standard-of-care regimen of high-dose chemotherapy and autologous stem-cell transplant.

The results of a pre-specified interim analysis conducted by an independent review committee showed that the study met its primary endpoint. Data showed a clinically meaningful and highly statistically significant improvement in event-free survival, as well as key secondary endpoints of complete response rate and progression-free survival compared to standard of care. The safety results were consistent with the known safety profile of Breyanzi for the treatment of LBCL in the third-line setting.

Bristol Myers will complete an evaluation of the TRANSFORM data and looks forward to sharing the results at an upcoming medical conference, as well as with health authorities.

Bristol-Myers’ shares have gained 7.9% year to date against the industry's decline of 1.9%.
curncman
Posts: 1077
Joined: Fri Jun 26, 2020 8:27 am

Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort

Post by curncman »

Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort

https://www.yahoo.com/finance/news/auto ... 43037.html

Vandana Singh
Fri, June 11, 2021, 9:43 AM

Autolus Therapeutics plc (NASDAQ: AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) and r/r Adult Acute Lymphoblastic Leukemia (ALL) trials.

The data were presented at the European Hematology Association Virtual Congress 2021.

As of the cut-off date of May 17, obe-cel was well-tolerated and demonstrated a favorable safety profile in adult patients with r/r low-grade B-cell lymphoma, despite a high disease burden.

All treated patients achieved complete metabolic remission.

Mild cytokine release syndrome (CRS) was reported in 4 patients and moderate CRS in 1 patient.

No immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.

At a median follow-up of 6 months, 8/9 patients were disease-free at last follow-up, with one patient relapsed but was rescued with radiotherapy.

One patient died of a COVID-19 infection at month 5.6 while in complete metabolic remission.

In 20 patients in Cohort A with r/r ALL, the therapy was well tolerated, with no patients experiencing severe or higher CRS.

Three patients, all of whom had high leukemia burden (over 50% blasts), experienced severe ICANS that resolved with steroids.

Of the 20 patients evaluable for efficacy, 17 patients achieved a minimum residual disease-negative complete remission at one month.

Across all treated patients, event-free survival (EFS) at twelve months and twenty-four months is 50.2%, with median EFS not being reached.
Post Reply